Ahmed Asma, Ajmeera Rajunaik, Bagrecha Mahavir Satishchand, Shetty Ganaraj, Mallika D, Sharma Priyanka, Tiwari Raj Kumar
Department of ENT, Government Medical Hospital, Kathua, Jammu and Kashmir, India.
Department of ENT, Government Medical College, Buapalalli, Telangana, India.
J Pharm Bioallied Sci. 2024 Jul;16(Suppl 3):S2621-S2623. doi: 10.4103/jpbs.jpbs_409_24. Epub 2024 Jul 1.
To assess how well steroidal nasal sprays and oral steroids work for treating CRS.
Two hundred patients with CRS were included in a randomized controlled experiment. The patients were split into two groups: Group B received steroidal nasal sprays (fluticasone propionate 110 mcg/day in each nostril for 12 weeks) and Group A received oral steroids (prednisolone 30 mg/day for 14 days, followed by tapering over 7 days). The "Sino-Nasal Outcome Test (SNOT-22)" was used to quantify improvement in symptoms, the "Rhinosinusitis Disability Index (RSDI)" was used to measure quality of life, and the recurrence rate was measured at the 6-month follow-up.
At 12 weeks, SNOT-22 and RSDI scores significantly improved with both oral steroids and steroidal nasal sprays ( < 0.05). At the 6-month follow-up, however, oral steroids had a greater recurrence rate (25% vs. 12%, = 0.02) when compared to steroidal nasal sprays. The two groups' adverse effects were similar and of low severity.
In conclusion, nasal sprays containing steroids seem to be a safer and more successful option than oral steroids for treating CRS, making them worthy of being used as the first line of treatment.
评估类固醇鼻喷雾剂和口服类固醇治疗慢性鼻-鼻窦炎(CRS)的效果。
200例CRS患者纳入一项随机对照试验。患者分为两组:B组接受类固醇鼻喷雾剂治疗(每侧鼻孔每日使用110微克丙酸氟替卡松,持续12周),A组接受口服类固醇治疗(泼尼松龙每日30毫克,持续14天,随后在7天内逐渐减量)。采用“鼻-鼻窦结局测试(SNOT-22)”量化症状改善情况,采用“鼻窦炎残疾指数(RSDI)”衡量生活质量,并在6个月随访时测量复发率。
12周时,口服类固醇和类固醇鼻喷雾剂治疗后SNOT-22和RSDI评分均显著改善(<0.05)。然而,在6个月随访时,与类固醇鼻喷雾剂相比,口服类固醇的复发率更高(25%对12%,P = 0.02)。两组的不良反应相似且严重程度较低。
总之,对于治疗CRS,含类固醇的鼻喷雾剂似乎比口服类固醇更安全、更有效,值得作为一线治疗用药。